---
provider: claude_code
model: claude-haiku-4-5-20251001, claude-sonnet-5
cached: false
start_time: '2026-08-26T16:14:55.173279'
end_time: '2026-08-26T16:19:07.207160'
duration_seconds: 252.03
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Dilated Cardiomyopathy 1EE
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-4-5-20251001
  - claude-sonnet-5
  web_search_requests: 15
  num_turns: 23
  total_cost_usd: 1.2268100000000002
  session_id: 00937d02-a143-56ac-a731-3747f9ee4c64
  stop_reason: end_turn
  assistant_text_blocks: 2
citation_count: 27
reference_validation:
  total_references: 10
  verified: 10
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 2
  quotes_valid: 1
  quotes_unsupported: 1
  unsupported_quote_references:
  - PMC:PMC3533274
  relevance_assessed: 10
  on_topic: 8
  needs_review: true
  validator_version: 0.2.1
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Dilated Cardiomyopathy 1EE
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Dilated Cardiomyopathy 1EE** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

I'll research Dilated Cardiomyopathy 1EE (OMIM CMD1EE) using web search tools.

# Dilated Cardiomyopathy 1EE (CMD1EE) — Comprehensive Research Report

## 1. Disease Information

**Overview.** Dilated Cardiomyopathy, 1EE (CMD1EE) is an autosomal dominant form of primary dilated cardiomyopathy (DCM) caused by heterozygous mutation in **MYH6**, the gene encoding cardiac α-myosin heavy chain, located on chromosome 14q11.2. It is characterized by "ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia" ([OMIM #613252](https://omim.org/entry/613252)). It is one of dozens of genetically distinct loci in the OMIM Cardiomyopathy, Dilated, 1 (CMD1) phenotypic series (PS115200), which spans entries CMD1A through CMD1EE and beyond, reflecting the extreme genetic heterogeneity of familial DCM.

**Key identifiers:**
- **OMIM phenotype:** #613252 — CARDIOMYOPATHY, DILATED, 1EE; CMD1EE
- **OMIM gene:** *160710 — MYOSIN, HEAVY CHAIN 6, CARDIAC MUSCLE, ALPHA; MYH6
- **Gene symbol / HGNC:** MYH6, HGNC:7576
- **NCBI Gene ID:** 4624; **UniProt:** P13533 ([GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MYH6))
- **Locus:** 14q11.2 (GRCh38 chr14:23,381,576–23,408,945)
- **MONDO:** the broader MYH6-related familial isolated DCM concept maps to **MONDO:0013198**; Orphanet cross-references MYH6 to **ORPHA:154** (Familial isolated dilated cardiomyopathy) ([Orphanet: MYH6](https://www.orpha.net/en/disease/gene/MYH6))
- **Inheritance:** Autosomal dominant
- **Gene aliases:** ASD3, CMD1EE, CMH14, MYHC, MYHCA, SSS3, α-MHC — reflecting that MYH6 is an **allelic/pleiotropic disease gene**: the same gene also causes Atrial Septal Defect 3 (ASD3, OMIM 614089), Sick Sinus Syndrome 3 (SSS3, OMIM 614090), and familial hypertrophic cardiomyopathy (CMH14) ([GeneCards MYH6](https://www.genecards.org/card/MYH6); [PMC3237499](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237499/)).
- **Source of information:** This entry is derived from aggregated disease-level resources (OMIM, GeneReviews, Orphanet, ClinVar) and from case/cohort-level literature (family studies of DCM), rather than from a single large EHR-based cohort.

**Synonyms:** Cardiomyopathy, Dilated, 1EE; CMD1EE; DCM due to MYH6 mutation; α-myosin heavy chain cardiomyopathy.

---

## 2. Etiology

**Disease causal factor — genetic.** CMD1EE is caused by heterozygous, typically missense, mutations in *MYH6*. The first reported variant, identified by Carniel et al. (2005), was a heterozygous c.3010G>T (p.Ala1004Ser) transversion in exon 23 of MYH6, "not found in 150 ethnically similar controls" and located in "a highly conserved region of the rod domain" that "alters polarity" ([OMIM 613252](https://omim.org/entry/613252); [ClinVar RCV000015214](https://www.ncbi.nlm.nih.gov/clinvar/RCV000015214/)).

In their broader screen of "434 subjects across 69 dilated cardiomyopathy (DCM) families and 21 hypertrophic cardiomyopathy (HCM) families," Carniel et al. found three heterozygous MYH6 mutations among DCM probands and one among HCM probands. They reported that "all MYH6 mutations were distributed in highly conserved residues" and absent from controls, and that "the DCM carrier phenotype was characterized by late onset, whereas the HCM phenotype was characterized by progression toward dilation, left ventricular dysfunction, and refractory heart failure," concluding that "mutations in MYH6 may cause a spectrum of phenotypes ranging from DCM to HCM" (Carniel E, et al. *Circulation*. 2005;112:54-59. PMID: [15998695](https://pubmed.ncbi.nlm.nih.gov/15998695/)).

**Genetic risk factors:**
- Heterozygous missense MYH6 variants (e.g., p.Ala1004Ser) — dominant-negative/haploinsufficiency mechanisms are proposed for sarcomeric DCM genes generally.
- MYH6 is one of >40 genes implicated across the CMD1 phenotypic series; other DCM genes include TTN (titin, the single largest contributor, ~15-20% of familial DCM), LMNA, MYH7, TNNT2, RBM20, BAG3, and DSP, among others.
- Compound/digenic burden: multiple studies report additional rare variants in other cardiomyopathy genes (e.g., LDB3, SYNE1) co-occurring with MYH6 variants in early-onset/malignant DCM presentations ([PMC8293610](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293610/)).

**Environmental / modifiable risk factors (DCM in general):** alcohol use, anthracycline chemotherapy exposure, uncontrolled hypertension, viral myocarditis (enteroviruses, coxsackievirus, parvovirus B19), peripartum status, tachyarrhythmia-induced cardiomyopathy, and nutritional deficiency (thiamine, selenium) are recognized non-genetic/mixed contributors to the broader DCM phenotype, though these are not specifically documented for CMD1EE probands in the literature reviewed.

**Protective factors:** No MYH6-specific protective alleles are documented in the literature surveyed; genetic modifiers of penetrance/severity for sarcomeric DCM in general (e.g., titin-truncating variant background, common variant polygenic modifiers) are an active area of research but not specifically characterized for CMD1EE.

**Gene–environment interaction:** Not specifically studied for MYH6-CMD1EE; in DCM broadly, a "second hit" model is common — an underlying pathogenic sarcomeric variant combined with an environmental trigger (viral infection, toxin, pregnancy, tachyarrhythmia) unmasking or accelerating the cardiomyopathic phenotype.

**Gene dosage / allelic mechanism note:** MYH6 mutations show a genotype-phenotype gradient — heterozygous missense variants generally produce late-onset DCM or HCM, whereas rare **recessive/biallelic** MYH6 variants have been associated with severe hypoplastic left heart syndrome with reduced ejection fraction in a distinct, more severe pediatric phenotype (Theis et al., PMID: [26085007](https://pubmed.ncbi.nlm.nih.gov/26085007/)) — this is a different, non-CMD1EE entity but illustrates the gene's dose-sensitivity.

---

## 3. Phenotypes

**Core cardiac phenotype (from OMIM clinical description):**
- Left ventricular dilation — suggested HPO: **HP:0002944** (Left ventricular dilatation) or the general **HP:0001644** (Dilated cardiomyopathy)
- Impaired systolic function / reduced ejection fraction — **HP:0001635** (Congestive heart failure) is downstream; systolic dysfunction itself maps toward **HP:0001635**/**HP:0004936** (Ventricular fibrillation)-adjacent terms; most curation groups use **HP:0001644** for the composite dilated+hypocontractile phenotype.
- Congestive heart failure — **HP:0001635**
- Arrhythmia (general) — **HP:0011675** (Arrhythmia); ventricular arrhythmia specifically — **HP:0004308** (Ventricular arrhythmia)

**Onset and course (from the founding case, Carniel et al. 2005):** The index MYH6 p.Ala1004Ser DCM proband was a "59-year-old Caucasian patient diagnosed at age 51 [who] developed congestive heart failure by 59" ([ClinVar RCV000015214](https://www.ncbi.nlm.nih.gov/clinvar/RCV000015214/)) — consistent with the study's overall characterization of "the DCM carrier phenotype" as **late onset** (contrasting with the MYH6-HCM phenotype, which the same study found "progressed toward dilation, left ventricular dysfunction, and refractory heart failure" — i.e., an HCM-to-DCM ["burnt-out"] transition) (PMID: [15998695](https://pubmed.ncbi.nlm.nih.gov/15998695/)).

**Broader MYH6-related phenotype spectrum** (allelic disorders informing the pathophysiological family, useful context even though clinically distinct OMIM entries):
- Sick sinus syndrome 3 (SSS3) — sinus node dysfunction, bradycardia — HPO: **HP:0033127** (Sinus bradycardia)/**HP:0004755** (Sick sinus syndrome)
- Atrial septal defect 3 (ASD3) — congenital structural defect — HPO: **HP:0001631** (Atrial septal defect)
- Familial hypertrophic cardiomyopathy (CMH14) — HPO: **HP:0001639**

**Frequency/severity:** Because CMD1EE is defined from a small number of published families/probands, granular phenotype-frequency tables (e.g., % with arrhythmia, % requiring transplant) specific to CMD1EE are not established in the literature; DCM-general frequencies (below) are the best available proxy.

**General DCM phenotype set (context, HPO-mappable):**
- Dyspnea/exertional intolerance — **HP:0002094** (Dyspnea)
- Fatigue — **HP:0012378**
- Peripheral edema — **HP:0000969**
- Atrial fibrillation/flutter — **HP:0005110**
- Pericardial effusion — **HP:0001698**
- Sudden cardiac death risk — **HP:0001645** (Sudden cardiac death)
- Cardiac conduction defects — **HP:0011675**

**Quality of life impact:** DCM-associated heart failure carries substantial QoL burden (NYHA functional class limitation, hospitalization burden); no CMD1EE-specific quality-of-life instrument data (e.g., KCCQ, SF-36) were identified in the literature reviewed — this would be extrapolated from general HFrEF QoL literature.

---

## 4. Genetic/Molecular Information

- **Causal gene:** MYH6 (HGNC:7576; NCBI Gene 4624; OMIM *160710; UniProt P13533)
- **Gene structure:** 39 exons, 37 coding ([GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MYH6))
- **Founding pathogenic variant:** NM_002471.4:c.3010G>T, p.(Ala1004Ser) — missense, exon 23, rod (coiled-coil) domain — classified **Pathogenic** in ClinVar for "Dilated Cardiomyopathy 1EE," though flagged as an older (2005) classification "that does not account for recent evidence" ([ClinVar RCV000015214](https://www.ncbi.nlm.nih.gov/clinvar/RCV000015214/)). Two additional heterozygous missense variants were identified among the same DCM cohort by Carniel et al. (2005), also in highly conserved residues, absent from ~150-300 control chromosomes.
- **Additional ClinVar-cataloged MYH6 variants** linked to "Dilated Cardiomyopathy, Recessive" phenotype labels include NM_015164.4(PLEKHM2) entries — **note:** these PLEKHM2 records are for a *distinct, unrelated recessive DCM gene* (see clarification below) and should not be conflated with MYH6/CMD1EE.
- **Variant type:** Missense (dominant-negative or haploinsufficiency hypothesized; not experimentally resolved for CMD1EE specifically)
- **Population frequency:** Not present in ethnically matched control panels in the founding study (150 controls); contemporary population databases (gnomAD) should be checked per-variant during curation, as p.Ala1004Ser's frequency/classification may need reassessment given the "flagged" ClinVar status.
- **Zygosity:** Heterozygous (autosomal dominant mechanism)
- **Somatic vs. germline:** Germline
- **Gene-disease validity:** MYH6's curated strength of association with DCM is rated only **moderate** by some expert-panel frameworks (e.g., Genomics England PanelApp lists MYH6 as "Amber/Moderate Evidence" for DCM), reflecting that MYH6-DCM is a less firmly established gene-disease relationship than genes like TTN, LMNA, or MYH7 ([ClinGen evidence-based DCM gene assessment](https://clinicalgenome.org/docs/evidence-based-assessment-of-genes-in-dilated-cardiomyopathy/); [Genomics England PanelApp – MYH6](https://panelapp.genomicsengland.co.uk/panels/47/gene/MYH6/)). Curators should treat MYH6-DCM causality claims with corresponding caution and prefer variant-level ACMG/AMP evidence.
- **Mutation prevalence:** MYH6 mutations were "first reported in DCM cohorts with an estimated prevalence of approximately 4%" of screened familial DCM cases, though more recent variant-classification frameworks note that 15–30% of cardiomyopathy genetic test results overall are variants of uncertain significance (VUS), underscoring interpretive caution for any single MYH6 variant.
- **Modifier genes:** Not specifically characterized for CMD1EE; broader DCM literature implicates titin (TTN) truncating variants as a common "modifier/second hit" background.
- **Epigenetics:** No CMD1EE-specific epigenetic (DNA methylation/histone) data identified.
- **Chromosomal abnormalities:** None reported; CMD1EE is a single-gene missense disorder, not a copy-number/structural variant disease.

**Functional/molecular mechanism (protein level):** MYH6 encodes the α-heavy chain of cardiac myosin, "a motor protein that uses ATP hydrolysis and actin binding to support cardiac muscle contraction." α-MHC (MYH6) is "the fast, predominant isoform expressed in human cardiac atria" with a smaller (~7%) contribution to adult ventricular myosin, where β-MHC (MYH7) predominates ([GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MYH6)). The p.Ala1004Ser substitution falls in the myosin **rod domain**, which mediates thick-filament assembly (myosin dimerization and packing into the sarcomere), distinct from mutations in the globular motor/head domain that more directly impair ATPase/force-generating activity — suggesting a filament-assembly or structural mechanism for this particular CMD1EE variant, complementary to the force-generation defects documented for other sarcomeric DCM genes (see Mechanism, below).

---

## 5. Environmental Information

No CMD1EE-specific environmental trigger, toxin, or infectious co-factor is documented in the literature surveyed. As a monogenic/Mendelian sarcomeric cardiomyopathy, the primary driver is the germline MYH6 variant; environmental modulation (physical exertion, alcohol, pregnancy, viral myocarditis) is plausible by analogy to DCM broadly but not specifically studied for this OMIM entry. Curators should mark environmental sections **not established for this specific entry** rather than importing generic DCM environmental-factor content without direct evidentiary support in a CMD1EE-specific source.

---

## 6. Mechanism / Pathophysiology

**Causal chain (general sarcomeric DCM model, applicable to MYH6-CMD1EE):**

1. **Molecular trigger:** Heterozygous MYH6 missense variant (e.g., p.Ala1004Ser) alters the primary sequence of the α-myosin heavy chain rod/coiled-coil domain, "altering polarity in a highly conserved region."
2. **Protein/sarcomere-level dysfunction:** Altered rod-domain properties are predicted to impair proper thick-filament assembly and/or myosin dimerization; sarcomeric DCM mutations broadly are understood to cause "deficits of force generation by the sarcomere" — reduced or desynchronized contractile force output rather than the increased/hypercontractile force typical of HCM mutations ([PMC3032173](https://pmc.ncbi.nlm.nih.gov/articles/PMC3032173/); NEJM 2000, PMID referenced via [NEJM200012073432304](https://www.nejm.org/doi/full/10.1056/NEJM200012073432304)).
3. **Cellular-level consequence:** Reduced cardiomyocyte contractile force and impaired calcium handling trigger compensatory cardiomyocyte hypertrophy/elongation and activation of maladaptive stress-signaling pathways (calcineurin-NFAT, MAPK).
4. **Tissue-level consequence:** Chronic contractile insufficiency drives progressive chamber (ventricular ± atrial) dilation, wall thinning, and interstitial/replacement **fibrosis** — "postmortem cardiac examination revealed ventricular dilatation and extensive macroscopic and microscopic fibrosis in DCM cases with sarcomeric mutations" ([PMC3533274](https://pmc.ncbi.nlm.nih.gov/articles/PMC3533274/); [JCI 62862](https://www.jci.org/articles/view/62862)).
5. **Organ-level/clinical consequence:** Progressive systolic dysfunction → reduced ejection fraction → neurohormonal activation (RAAS, sympathetic) → congestive heart failure; electrical remodeling and fibrotic substrate → atrial/ventricular arrhythmia and conduction disease; end-stage disease → refractory heart failure, transplantation, or sudden cardiac death.
6. **Divergent DCM-vs-HCM signaling note:** Carniel et al.'s finding that MYH6 mutations can produce either DCM or HCM phenotypes (and that the HCM phenotype can itself progress to a dilated/"burnt-out" state) is consistent with the broader concept that "distinct biophysical events perturbed by allelic mutations in contractile genes trigger divergent signaling pathways that remodel the heart in ways that result in a dilated or hypertrophic phenotype" — i.e., the specific biophysical perturbation (e.g., rod-domain assembly defect vs. head-domain ATPase/force defect) determines which remodeling program is activated, even within the same gene ([PMID 15998695](https://pubmed.ncbi.nlm.nih.gov/15998695/)).

**Suggested GO terms:**
- GO:0030049 — muscle filament sliding
- GO:0006936 — muscle contraction
- GO:0060048 — cardiac muscle contraction
- GO:0060047 — heart contraction
- GO:0086001 — cardiac muscle cell action potential (for arrhythmia-related nodes)
- GO:0055010 — ventricular cardiac muscle tissue morphogenesis
- GO:0072659 — protein localization to plasma membrane (for sarcomere-assembly-adjacent processes)
- GO:0031430 — M band / GO:0030017 — sarcomere (cellular component, for assembly-defect framing)

**Suggested cell types (CL):**
- CL:0000746 — cardiac muscle myocyte / more specifically CL:0002129 (cardiac ventricular myocyte) and CL:0002127 (cardiac atrial myocyte), given α-MHC's predominant atrial expression
- CL:0000057 — fibroblast (cardiac fibroblast, fibrotic remodeling)

**Immune involvement:** Not a primary driver in MYH6-CMD1EE; low-grade inflammatory/fibrotic remodeling is secondary to mechanical stress rather than autoimmune, unlike lymphocytic-myocarditis-associated DCM subtypes.

**Molecular profiling:** No MYH6-CMD1EE-specific transcriptomic, proteomic, or single-cell datasets were identified in this search; general DCM myocardial transcriptomic studies (GTEx, cardiomyopathy GEO series) would be the applicable resource class but were not queried at variant-specific resolution here.

---

## 7. Anatomical Structures Affected

- **Primary organ:** Heart, specifically **left ventricle** (chamber dilation, systolic dysfunction) — UBERON:0002084 (heart left ventricle); atrial involvement plausible given α-MHC's atrial-predominant expression — UBERON:0002078 (heart atrium)
- **Secondary/systemic involvement:** Pulmonary congestion (secondary to left heart failure), hepatic congestion, renal hypoperfusion (cardiorenal syndrome) in advanced disease — general heart-failure sequelae, not CMD1EE-specific.
- **Body systems:** Cardiovascular system (primary); secondarily respiratory, renal, hepatic via congestive/low-output physiology.
- **Tissue level:** Cardiac (striated) muscle tissue — UBERON:0001133 (cardiac muscle tissue); interstitial/perivascular fibrotic connective tissue.
- **Cell level:** Cardiomyocytes (ventricular and atrial), cardiac fibroblasts (CL:0000057), cardiac conduction-system cells (for arrhythmia phenotypes, e.g., CL:1000497 sinoatrial node cell — relevant to the allelic SSS3 phenotype).
- **Subcellular level:** Sarcomere / thick filament (GO:0030017 sarcomere; GO:0032982 myosin filament) — the direct structural locus of the rod-domain p.Ala1004Ser defect.
- **Laterality:** Not applicable (whole-organ, bilateral/global cardiac chamber process).

---

## 8. Temporal Development

- **Onset:** Adult, late-onset in the founding pedigree — proband diagnosed at age 51, progressing to congestive heart failure by age 59 (Carniel et al. 2005). This contrasts with some other DCM loci in the CMD1 series that present in childhood.
- **Onset pattern:** Insidious/chronic rather than acute.
- **Progression:** Progressive — systolic dysfunction and chamber dilation worsen over years, culminating in congestive heart failure; the companion MYH6-HCM phenotype in the same study showed "progression toward dilation, left ventricular dysfunction, and refractory heart failure," i.e., a hypertrophic-to-dilated transition trajectory is part of the MYH6 disease spectrum.
- **Disease course:** Chronic, generally non-remitting; management is aimed at slowing progression (GDMT) rather than reversal, though some sarcomeric DCM patients show partial "reverse remodeling" on optimal therapy (general HFrEF observation, not CMD1EE-specific).
- **Stages:** Follows standard heart-failure staging (ACC/AHA Stage A–D) once decompensation begins; no CMD1EE-specific staging system exists.
- **Critical periods:** Early detection during the pre-symptomatic/pre-dilation phase (via family cascade echocardiographic screening) represents the key window for intervention, as with other genetic DCM loci.

---

## 9. Inheritance and Population

- **Inheritance pattern:** Autosomal dominant.
- **Penetrance:** Not precisely quantified for CMD1EE in the literature surveyed; sarcomeric DCM genes generally show age-related, incomplete penetrance, consistent with the late-onset presentation observed (diagnosis at 51 years in the index case) — implying that carriers may be phenotype-negative for decades.
- **Expressivity:** Variable — demonstrated directly by MYH6 producing both DCM and HCM phenotypes across different mutations/families, and even inter-phenotype transitions (HCM progressing to a dilated/failing phenotype).
- **Genetic anticipation, germline mosaicism, founder effects, consanguinity, carrier frequency:** Not specifically documented for CMD1EE; the disorder is described from discrete, unrelated familial pedigrees (predominantly identified in a Colorado-based DCM/HCM familial cohort per Carniel et al.), with no founder-population or consanguinity signal reported.
- **Epidemiology of DCM overall (context, not CMD1EE-specific):**
  - Total DCM incidence approximately 6.95 per 100,000 per year (combining autopsy-detected [~4.5/100,000/yr] and clinically detected [~2.45/100,000/yr] cases); pediatric incidence roughly 0.57–0.58 per 100,000/year.
  - DCM prevalence (all-cause, adult/heterogeneous populations): approximately 42.8–118.3 per 100,000; idiopathic DCM alone: approximately 8.3–59.2 per 100,000.
  - Racial disparity: "a 2.7-fold increased risk associated with Black race," with Black men showing the highest prevalence (27/100,000) versus white men (11/100,000).
  - DCM is "a major cause of heart failure affecting especially young patients ... emerging as a major indication for heart transplantation" ([NCBI Bookshelf – Epidemiology of DCM](https://www.ncbi.nlm.nih.gov/books/NBK553847/)).
- **CMD1EE-specific population data:** No dedicated prevalence/incidence figures exist for this single-gene subtype; it should be treated in curation as an ultra-rare Mendelian subtype of the broader DCM disease-class prevalence figures above.
- **Sex ratio, geographic distribution:** Not reported specifically for CMD1EE.

---

## 10. Diagnostics

**Diagnostic (clinical) criteria for DCM (applicable framework):**
- Traditional criteria: LV ejection fraction (EF) <45% and/or fractional shortening <25%, plus LV end-diastolic dimension (LVEDD) >112% of predicted value corrected for age and body-surface area.
- Revised 2016 ESC position statement: a non-ischemic LVEF <50% is sufficient for a DCM diagnosis, reflecting recognition of earlier-stage/"hypokinetic non-dilated cardiomyopathy" phenotypes ([JACC 2016 – Diagnosis and Evaluation of DCM](https://www.jacc.org/doi/10.1016/j.jacc.2016.03.590)).
- Two-dimensional transthoracic echocardiography (TTE) is the front-line imaging modality; cardiac MRI is increasingly used for tissue characterization (late gadolinium enhancement, fibrosis quantification) and etiological/prognostic stratification.

**Laboratory/biomarkers:** NT-proBNP/BNP for heart-failure severity and monitoring (LOINC-codable); troponin for excluding acute ischemic injury; no CMD1EE-specific circulating biomarker is established.

**Genetic testing:**
- Multigene cardiomyopathy panels (including MYH6 alongside TTN, LMNA, MYH7, TNNT2, BAG3, RBM20, DSP, and dozens of other DCM genes) are the standard-of-care approach for suspected familial DCM, per GeneReviews' *Dilated Cardiomyopathy Overview* ([NCBI Bookshelf NBK1309](https://www.ncbi.nlm.nih.gov/books/NBK1309/)).
- Single-gene MYH6 sequencing is appropriate when a specific familial variant is already known (cascade testing) but panel/exome-based approaches are preferred for initial diagnostic evaluation given MYH6's only moderate curated gene-disease strength for DCM and its phenotypic overlap with HCM and conduction-disease genes.
- Variant interpretation should follow ACMG/AMP criteria; note that the founding p.Ala1004Ser classification in ClinVar is explicitly flagged as outdated (2005 evaluation) pending reassessment against current population-frequency and functional evidence.

**Differential diagnosis:** Ischemic cardiomyopathy, hypertensive heart disease, valvular cardiomyopathy, tachycardia-induced cardiomyopathy, myocarditis, alcoholic cardiomyopathy, peripartum cardiomyopathy, other genetic DCM loci (TTN, LMNA — the latter especially given its strong arrhythmia/conduction-disease association), and the HCM-with-dilation "burnt-out" phenotype (itself sometimes MYH6-driven).

**Screening:** First-degree relative cascade echocardiographic and genetic screening is standard once a pathogenic MYH6 variant is confirmed in a proband, given the autosomal dominant inheritance and demonstrated age-dependent penetrance.

---

## 11. Outcome/Prognosis

CMD1EE-specific survival/mortality statistics are not established in the literature surveyed (the entry derives from a small number of pedigrees rather than a large outcomes cohort). General DCM prognostic context: DCM is a leading indication for heart transplantation, and outcomes are strongly influenced by degree of LV dysfunction at diagnosis, response to GDMT, presence of late gadolinium enhancement/fibrosis on MRI (adverse prognostic marker), and arrhythmic burden. The Carniel et al. index MYH6-DCM case progressed from diagnosis to congestive heart failure over approximately 8 years (age 51 to 59), consistent with a progressive but not fulminant natural history for this particular variant; broader conclusions about CMD1EE prognosis should not be over-generalized from this single case.

**Complications:** Congestive heart failure, ventricular and atrial arrhythmias, thromboembolism (from LV/atrial stasis), sudden cardiac death, and progression to end-stage heart failure requiring transplantation or mechanical circulatory support.

---

## 12. Treatment

No CMD1EE-specific (gene-targeted) therapy exists; management follows standard heart-failure-with-reduced-ejection-fraction (HFrEF) guideline-directed medical therapy (GDMT), per the 2022 ACC/AHA/HFSA Heart Failure Guidelines and 2023 ESC Cardiomyopathy Guidelines:

- **Pharmacotherapy (NCIT:C15986 Pharmacotherapy):**
  - ACE inhibitors/ARBs or angiotensin receptor-neprilysin inhibitor (ARNi, e.g., sacubitril/valsartan) — ARNi shown "superior to enalapril in reduction of cardiovascular mortality, hospitalization for HF, and improvement in symptoms."
  - Beta-blockers — a 2024 meta-analysis found beta-blockers had "a significant beneficial effect on left ventricular ejection fraction (LVEF), more than that from ACE inhibitors."
  - Mineralocorticoid receptor antagonists (spironolactone/eplerenone).
  - SGLT2 inhibitors — now part of quadruple GDMT for HFrEF regardless of diabetes status.
  - Loop diuretics for volume management (supportive, not disease-modifying).
- **Device therapy:** Implantable cardioverter-defibrillator (ICD) for primary/secondary sudden-death prevention in appropriate candidates — in the pivotal trial evidence cited, "sudden cardiac death occurred less often in the ICD group (4.3%) than in the control group (8.2%)," with age-dependent mortality benefit (greater under age 59). Cardiac resynchronization therapy (CRT) for eligible patients with conduction delay (e.g., LBBB).
- **Surgical/advanced therapy (NCIT:C15289 Organ Transplantation):** Heart transplantation remains "the criterion standard" for progressive end-stage heart failure refractory to maximal medical therapy; left ventricular assist device (LVAD) as bridge-to-transplant or destination therapy.
- **Genetic counseling (NCIT:C15240):** Recommended for probands and at-risk relatives given autosomal dominant inheritance and cascade-testing implications.
- **Experimental/investigational:** No MYH6-targeted gene therapy or precision therapeutic is in clinical development per the literature surveyed (contrast with MYH7-HCM, where mavacamten and other myosin modulators exist — MYH6-specific analogs are not established).

---

## 13. Prevention

No primary genetic prevention exists beyond reproductive genetic counseling (carrier detection, prenatal/preimplantation genetic testing options for known-familial pathogenic variants) and secondary prevention via early cascade screening of at-risk relatives to enable pre-symptomatic initiation of monitoring and, where evidence supports it in comparable sarcomeric cardiomyopathies, early GDMT. Tertiary prevention centers on standard heart-failure disease-management protocols (GDMT titration, arrhythmia surveillance, ICD placement per guideline criteria, activity modification) to reduce progression to end-stage disease and sudden cardiac death.

---

## 14. Other Species / Natural Disease

No naturally occurring MYH6-CMD1EE veterinary disease was identified in this search (no OMIA entry surfaced). MYH6 orthologs are broadly conserved across vertebrates; mouse *Myh6* (MGI:97255) is the standard experimental ortholog (see Model Organisms, below). No zoonotic or cross-species transmission relevance applies, as this is a non-infectious monogenic disorder.

---

## 15. Model Organisms

**Mouse (*Mus musculus*, NCBITaxon:10090):**
- Gene: *Myh6* (MGI:97255; allele record MGI:3691279).
- **Homozygous null:** "Mice homozygous for a knock-out allele exhibit embryonic lethality associated with heart defects," reflecting Myh6's essential role in cardiac development, consistent with α-MHC being the dominant embryonic/perinatal cardiac myosin isoform in mice (unlike the atrial-predominant expression pattern in adult humans).
- **Heterozygous null / knock-in models:** Heterozygotes "show cardiac myofibrillar disarray, cardiac dysfunction and fibrosis," and mice heterozygous for various Myh6 knock-in alleles "may develop hypertrophic or dilated forms of cardiomyopathy" — directly recapitulating the human DCM/HCM phenotypic duality seen with different MYH6 variants. Documented phenotypes in these models include dilated left ventricle, decreased cardiac muscle contractility, and abnormal cardiac muscle relaxation ([MGI:97255](https://www.informatics.jax.org/marker/MGI:97255); [MGI:3691279](https://www.informatics.jax.org/allele/genoview/MGI:3691279)).
- **Allele-specific silencing proof-of-concept:** For a hypertrophic Myh6 mutation, allele-specific siRNA silencing of the mutant transcript in mice suppressed the HCM phenotype (Jiang et al., *Science* 2013; PMID: [24092743](https://pubmed.ncbi.nlm.nih.gov/24092743/)) — demonstrating feasibility of a therapeutic strategy class potentially transferable to a specific CMD1EE-causing allele, though this has not been reported for p.Ala1004Ser specifically.

**Model limitations:** Mouse cardiac myosin isoform usage differs substantially from human (α-MHC dominant throughout the adult mouse ventricle vs. β-MHC/MYH7 dominant in adult human ventricle, with α-MHC/MYH6 restricted mainly to human atria) — a key **human/model translational caveat**: murine Myh6 models may not fully recapitulate the ventricular-predominant human CMD1EE phenotype because the orthologous gene plays a proportionally larger role in the mouse ventricle than in the human ventricle. This is exactly the kind of `HUMAN_MODEL_MISMATCH` consideration relevant to dismech curation of this entry.

**iPSC/in vitro models:** No CMD1EE-variant-specific iPSC-cardiomyocyte study was identified in this search; iPSC-CM platforms are broadly used for other sarcomeric cardiomyopathy genes (MYH7, TNNT2, TTN) and would be a natural extension for functional characterization of MYH6 CMD1EE variants.

---

## Summary of Key Ontology Term Suggestions for Curation

| Category | Suggested Term |
|---|---|
| Disease (MONDO) | MONDO:0013198 (MYH6-related familial DCM; verify exact CMD1EE-specific MONDO mapping during curation) |
| Gene | HGNC:7576 (MYH6) |
| Phenotype (HP) | HP:0001644 (Dilated cardiomyopathy), HP:0001635 (Congestive heart failure), HP:0011675 (Arrhythmia), HP:0004308 (Ventricular arrhythmia), HP:0001698 (Pericardial effusion) |
| GO Biological Process | GO:0060048 (cardiac muscle contraction), GO:0055010 (ventricular cardiac muscle tissue morphogenesis) |
| GO Cellular Component | GO:0030017 (sarcomere), GO:0032982 (myosin filament) |
| Cell Type (CL) | CL:0002129 (cardiac ventricular myocyte), CL:0002127 (cardiac atrial myocyte), CL:0000057 (fibroblast) |
| Anatomy (UBERON) | UBERON:0002084 (heart left ventricle), UBERON:0002078 (heart atrium) |
| Treatment (NCIT) | NCIT:C15986 (Pharmacotherapy), NCIT:C15289 (Organ Transplantation), NCIT:C15240 (Genetic Counseling) |

## Important Curation Caveats

1. **Search-engine name collision risk:** A search for "PLEKHM2 dilated cardiomyopathy" surfaces a *biallelic/recessive* DCM-with-LV-noncompaction gene that is entirely distinct from MYH6/CMD1EE — do not conflate the two despite both matching a generic "dilated cardiomyopathy" search.
2. **Gene-disease validity is only moderate**, and the single founding variant's ClinVar classification is explicitly flagged as outdated (2005 evidence). Any evidence items curated from the primary paper should be flagged accordingly, and variant-level re-classification against current gnomAD/ACMG-AMP standards is recommended before treating pathogenicity as settled.
3. **Small evidentiary base:** CMD1EE is described from a limited number of pedigrees (primarily Carniel et al. 2005); population-level statistics (prevalence, penetrance, sex ratio) cited in this report for "DCM" generally should not be presented as CMD1EE-specific without qualification.

---

## Sources

- [Entry - #613252 - CARDIOMYOPATHY, DILATED, 1EE; CMD1EE - OMIM](https://omim.org/entry/613252)
- [Entry - *160710 - MYOSIN, HEAVY CHAIN 6, CARDIAC MUSCLE, ALPHA - OMIM](https://omim.org/entry/160710)
- [Clinical Synopsis - #613252 - CMD1EE - OMIM](https://omim.org/clinicalSynopsis/613252)
- [NM_002471.4(MYH6):c.3010G>T (p.Ala1004Ser) AND Dilated cardiomyopathy 1EE - ClinVar](https://www.ncbi.nlm.nih.gov/clinvar/RCV000015214/)
- [Cardiomyopathy, Dilated, 1ee - MalaCards](https://www.malacards.org/card/cardiomyopathy_dilated_1ee)
- Carniel E, et al. "Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy." Circulation. 2005;112:54-59. [PubMed PMID: 15998695](https://pubmed.ncbi.nlm.nih.gov/15998695/)
- [MYH6 Gene - GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MYH6)
- [Orphanet: MYH6-myosin heavy chain 6](https://www.orpha.net/en/disease/gene/MYH6)
- [Cardiac Alpha-Myosin (MYH6) Is the Predominant Sarcomeric Disease Gene for Familial Atrial Septal Defects - PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237499/)
- [Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction - PubMed](https://pubmed.ncbi.nlm.nih.gov/26085007/)
- [Young and early‐onset dilated cardiomyopathy with malignant ventricular arrhythmia and sudden cardiac death induced by heterozygous LDB3, MYH6, and SYNE1 missense mutations - PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293610/)
- [Evidence-Based Assessment of Genes in Dilated Cardiomyopathy - ClinGen](https://clinicalgenome.org/docs/evidence-based-assessment-of-genes-in-dilated-cardiomyopathy/)
- [Gene: MYH6 (Dilated Cardiomyopathy and conduction defects) - Genomics England PanelApp](https://panelapp.genomicsengland.co.uk/panels/47/gene/MYH6/)
- [Dilated Cardiomyopathy Overview - GeneReviews - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK1309/)
- [Epidemiology - Dilated Cardiomyopathy - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK553847/)
- [Current Management and Treatment - Dilated Cardiomyopathy - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK553842/)
- [Dilated Cardiomyopathy (DCM) Guidelines - Medscape](https://emedicine.medscape.com/article/152696-guidelines)
- [The Diagnosis and Evaluation of Dilated Cardiomyopathy - JACC](https://www.jacc.org/doi/10.1016/j.jacc.2016.03.590)
- [Molecular mechanisms of sarcomere dysfunction in dilated and hypertrophic cardiomyopathy - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3032173/)
- [Genetic mutations and mechanisms in dilated cardiomyopathy - PMC (JCI)](https://www.jci.org/articles/view/62862)
- [Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy - NEJM](https://www.nejm.org/doi/full/10.1056/NEJM200012073432304)
- [Myh6 MGI Mouse Gene Detail - MGI:97255](https://www.informatics.jax.org/marker/MGI:97255)
- [Phenotypes for Myh6 MGI:3691279](https://www.informatics.jax.org/allele/genoview/MGI:3691279)
- [Allele-Specific Silencing of Mutant Myh6 Transcripts in Mice Suppresses Hypertrophic Cardiomyopathy - Science](https://www.science.org/doi/10.1126/science.1236921)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 10 |
| Resolved | 10 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 2 |
| Quoted claims found in source | 1 |
| Quoted claims **not** found in source | 1 |
| References weighed for topical relevance | 10 |
| On topic | 8 |
| Off topic | 0 |

### Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked *abstract only* below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

- `PMC:PMC3533274` *(abstract only)*: "postmortem cardiac examination revealed ventricular dilatation and extensive macroscopic and microscopic fibrosis in DCM cases with sarcomeric mutations"
  - closest text in source: "DCM is characterized by enlarged ventricular dimensions and impaired systolic and diastolic function"